Stocks In Focus

Technical Forecasts: JAVA, GNBT, HTDS

Sun Microsystems, Hard to Treat Diseases, and Generex Biotechnology are reviewed by a chart technician.

Published: November 4, 2009 @ 11:25 AM PST
Rating N/A
As stocks start to give up their early gains, traders are reminded that the current environment calls for only the best of the best chart setup. Among the most decisive movers we've seen today are Generex Biotechnology Corporation (NASDAQ:GNBT), Sun Microsystems, Inc. (NASDAQ:JAVA), and Hard to Treat Diseases (PINK:HTDS). Here's a better look at each one.

We actually turned bearish on Hard to Treat Diseases (PINK:HTDS) several weeks ago, and as each support level was broken, our pessimistic call was made with growing conviction. Add another layer of it today.

Hard to Treat Diseases shares took a shot at a rebound on Tuesday when they ran right up into the falling resistance line I've been talking about for weeks. The rally was stopped cold there, and today's high from HTDS also seems to be confirming that line is a cap. In other words, more of the same.

The final blow could come today when/if Hard to Treat Diseases falls under $0.008.... a major Fibonacci line (61.8% retracement). HTDS fell under that line last week, but popped back above it with the recovery effort. If the stock falls under it a second time, that should be all she wrote.



--------------------------------------------------------------------
Sign-up for Free to Receive Future Commentary
and Trading Alerts on HTDS, JAVA, and GNBT.

--------------------------------------------------------------------

We last looked at Generex Biotechnology Corporation (NASDAQ:GNBT) on October 27th, warning you that the move under support at $0.56 was the trigger for a bigger move lower. I hope you were listening.

The breakdown did indeed take hold, sending Generex Biotechnology from $0.55 then to their current price of $0.50. Though up a little today after yesterday's new multi-week low, the effort from GNBT is tepid.

I still suspect Generex Biotechnology is on pace to revisit the March/April support level around $0.27. I'd like to see a little more selling volume from GNBT to feel fully comfortable with that idea, but the bearish effort has been fairly string without it.



And finally, Sun Microsystems, Inc. (NASDAQ:JAVA) has made a nice consolidation and reversal pattern over the last week and a half. I think the stock's going to emerge from this mess quite bullishly.

I really with I could pinpoint what it is I like about this chart of Sun Microsystems, simply because I think this it's a great pattern to keep in mind fort the future. I can't though. About the best I can do is describe how the (1) height of the consolidation after the tumble, (2) the decisive switch from red/bearish to green/bullish bars, and (3) the V-shaped bottom all combine to suggest JAVA is positioning for a bounce.

As for a target, I suppose the ceiling around $9.20 - where Sun Microsystems treaded water during Q3 - is the best one to start with. I'd be willing to hang onto JAVA as a potential breakout candidate after that though.



If you'd like to know of any changes in our opinion of GNBT, HTDS, or JAVA (or if we officially recommend them as trades), be sure to sign up for our free newsletter today. It's delivered weekly.

Rate It : 1 2 3 4 5

Post a Comment
 

Title of the comment

Content of the comment

 
Bookmark and Share

Get the SCN
Newsletter Today!

Find out WHAT's Hot and What's Not from Top Traders and Investors.

Gain Insight into Which Small Cap Growth Stocks Have the Potential for Monster Returns.

Identify Market Trends and Changes Before the Rest of the Crowd.

Whitelist Us

Having Trouble Getting Our Email Newsletter?  Whitelist Us.

Click here for more info...

Oct 16, 2009 @ 12:44 PM PDT
When the recession hit, Audiovox was already in the process of cutting its fat, whereas other companies were only just beginning.
Rating N/A

Thursday January 21, 2010 10:50 PM GMT
As incredible as it may seem, despite the 2.3% tumble we’ve seen the PowerShares QQQ Trust (ETF) (NASDAQ:QQQQ) suffer over the last week and a half, the fund is still not in a heap of technical trouble…. at least not on the surface. If you look at the bigger picture of the underlying market though, [...]
Wednesday January 20, 2010 4:54 PM GMT
The SPDR S&P 500 ETF (NYSE:SPY) has just broken a seven-month support line. Though the relatively unharmful 1.7% dip today hasn’t unwound the bulk of the gains for that timeframe - or even the gains for the last couple of weeks - the weight of those gains has quietly been taking a toll on SPY. [...]
Wednesday October 28, 2009 4:35 PM GMT
If you’re a fan of trading the SPDR S&P 500 Fund (NYSE:SPY), or any index vehicle for that matter, you may want to put your bearish hat on. It’s no secret that the market’s been sinking for the last few days - we’ve seen plenty of ebb and flow since March. What traders may not [...]
Monday March 30, 2009 2:50 PM GMT
Wow. It’s not too often stocks lose a collective 3% within the first 5 minutes of trading. I suspected we were due for a nasty pullback (the kind of dip I forecasted on Thursday), and sure enough, here it is. The S&P 500 has now given up 4.8% from Thursday’s high. Is this enough to [...]
SCN Newsletters
Saturday February 6, 2010 11:48 AM PST
The bulls certainly fought back hard in the second half of Friday's session, turning yet-another big loss into fairly decent gains. Was this the reversal sign we've been waiting for, or merely a fake-out move? Thoughts on the matter are below. First though, highlights from this week's community commentary...
Friday January 29, 2010 11:37 AM PST
Power3 Medical Products (PWRM), First Regional Bancorp (FRGB), SPDR Trust S&P 500 Fund (SPY), ImmuneRegen Biosciences Holdings (IRBS), and Provident Financial Holdings (PROV) are reviewed in depth. After that, we take an updated look at our market forecast. Stocks in Focus Up-Trend Outlook: PROV...
Friday January 22, 2010 9:12 AM PST
Is New Leaf Brands Inc. (OTC:NLEF) going to follow in the footsteps of Cadbury and land a big suitor (at a premium)? Maybe. We'll check out this young and growing company below. First though, let's take a look at this week's 'best' of from the community pages. The shortened list looks at Hana Biosciences...

This community is currently in beta and is constantly undergoing active development.  Please be patient as we strive to bring you a usable, full-featured community that you will enjoy.  If you should have any questions, problems, suggestions, feature requests, rants, and/or raves, please do not hesitate to let us know by writing us as : webmaster@smallcapnetwork.com.